EBSAM
EPZM

Eubel Brady & Suttman Asset Management’s Epizyme, Inc EPZM Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-460
Closed -$4K – 387
2021
Q2 		$4K Buy
+460
New +$3.88K ﹤0.01% 581

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's EPZM Position: Q3 2021 in Review

Eubel Brady & Suttman Asset Management sold out of Epizyme, Inc (EPZM) in Q3 2021, closing a stake of 460 shares — an estimated $4K sold.

Eubel Brady & Suttman Asset Management first reported a position in EPZM in Q2 2021 and held it in 1 quarter. The position peaked at $4K in Q2 2021. 116 funds tracked by Wall St. Rank hold EPZM as of Q3 2021.

  • Eubel Brady & Suttman Asset Management reported no remaining Epizyme, Inc position as of Q3 2021 after selling out during the quarter.
  • Eubel Brady & Suttman Asset Management sold 460 Epizyme, Inc shares in Q3 2021, an estimated $4K.
  • Eubel Brady & Suttman Asset Management first reported a position in Epizyme, Inc in Q2 2021 and held it in 1 quarter.
  • Eubel Brady & Suttman Asset Management's Epizyme, Inc position peaked at $4K in Q2 2021.
  • 116 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2021.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q3 2021, filed 5 Nov 2021.